Follow
David Polidori
David Polidori
Johnson & Johnson Innovative Medicine
Verified email at its.jnj.com
Title
Cited by
Cited by
Year
Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes
J Rosenstock, N Aggarwal, D Polidori, Y Zhao, D Arbit, K Usiskin, ...
Diabetes care 35 (6), 1232-1238, 2012
5262012
Canagliflozin, a novel inhibitor of sodium glucose co‐transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose …
S Sha, D Devineni, A Ghosh, D Polidori, S Chien, D Wexler, K Shalayda, ...
Diabetes, Obesity and Metabolism 13 (7), 669-672, 2011
3582011
Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized …
D Polidori, S Sha, S Mudaliar, TP Ciaraldi, A Ghosh, N Vaccaro, K Farrell, ...
Diabetes care 36 (8), 2154-2161, 2013
3342013
Apparatus and method for computer modeling type 1 diabetes
K Gadkar, H Kreuwel, T Paterson, D Polidori, S Ramanujan, LKM Shoda, ...
US Patent App. 11/377,614, 2007
3202007
Efficacy and safety of canagliflozin, a sodium–glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes
RR Henry, P Thakkar, C Tong, D Polidori, M Alba
Diabetes care 38 (12), 2258-2265, 2015
3052015
Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin
JP Bilezikian, NB Watts, K Usiskin, D Polidori, A Fung, D Sullivan, ...
The Journal of Clinical Endocrinology 101 (1), 44-51, 2016
2852016
Effect of the sodium glucose co‐transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus
S Sha, D Polidori, T Heise, J Natarajan, K Farrell, SS Wang, D Sica, ...
Diabetes, Obesity and Metabolism 16 (11), 1087-1095, 2014
2662014
Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models
Y Liang, K Arakawa, K Ueta, Y Matsushita, C Kuriyama, T Martin, F Du, ...
PloS one 7 (2), e30555, 2012
2602012
Sodium–glucose cotransporter inhibitors: effects on renal and intestinal glucose transport: from bench to bedside
S Mudaliar, D Polidori, B Zambrowicz, RR Henry
Diabetes care 38 (12), 2344-2353, 2015
2562015
Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co‐transporter 2 inhibitor, in subjects with type 2 diabetes mellitus
D Devineni, CR Curtin, D Polidori, MJ Gutierrez, J Murphy, S Rusch, ...
The Journal of Clinical Pharmacology 53 (6), 601-610, 2013
2452013
How strongly does appetite counter weight loss? Quantification of the feedback control of human energy intake
D Polidori, A Sanghvi, RJ Seeley, KD Hall
Obesity 24 (11), 2289-2295, 2016
2032016
Effects of canagliflozin on body weight and relationship to HbA1c and blood pressure changes in patients with type 2 diabetes
WT Cefalu, K Stenlöf, LA Leiter, JPH Wilding, L Blonde, D Polidori, J Xie, ...
Diabetologia 58, 1183-1187, 2015
1622015
Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes
K Cusi, F Bril, D Barb, D Polidori, S Sha, A Ghosh, K Farrell, NE Sunny, ...
Diabetes, Obesity and Metabolism 21 (4), 812-821, 2019
1502019
Effect of canagliflozin on liver function tests in patients with type 2 diabetes
LA Leiter, T Forst, D Polidori, DA Balis, J Xie, S Sha
Diabetes & metabolism 42 (1), 25-32, 2016
1372016
Roux-en-Y gastric bypass corrects hyperinsulinemia implications for the remission of type 2 diabetes
MA Reed, WJ Pories, W Chapman, J Pender, R Bowden, H Barakat, ...
The Journal of Clinical Endocrinology & Metabolism 96 (8), 2525-2531, 2011
1342011
Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes
D Polidori, A Mari, E Ferrannini
Diabetologia 57, 891-901, 2014
1312014
Determination of modal parameters from ambient vibration data for structural health monitoring
JL Beck, BS May, DC Polidori
First World Conference on Structural Control 2, 1994
1191994
Canagliflozin: a sodium glucose co‐transporter 2 inhibitor for the treatment of type 2 diabetes mellitus
N Rosenthal, G Meininger, K Ways, D Polidori, M Desai, R Qiu, M Alba, ...
Annals of the New York Academy of Sciences 1358 (1), 28-43, 2015
1112015
Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double‐blind, crossover study
S Sha, D Polidori, K Farrell, A Ghosh, J Natarajan, N Vaccaro, J Pinheiro, ...
Diabetes, Obesity and Metabolism 17 (2), 188-197, 2015
1102015
Clinical pharmacokinetic, pharmacodynamic, and drug–drug interaction profile of canagliflozin, a sodium-glucose co-transporter 2 inhibitor
D Devineni, D Polidori
Clinical pharmacokinetics 54, 1027-1041, 2015
1092015
The system can't perform the operation now. Try again later.
Articles 1–20